Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04016389 · ClinicalTrials.gov registry record · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
A NA study of Cervical Cancer, sponsored by University Health Network, Toronto.
- Recruiting
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 4
- Study locations
NCT04016389: Recruiting NA study of Cervical Cancer, sponsored by University Health Network, Toronto.
NCT04016389 is a NA study of Cervical Cancer that is actively recruiting participants, run by University Health Network, Toronto. The registered enrollment target is 31 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04016389, a NA study of Cervical Cancer, is actively recruiting participants, sponsored by University Health Network, Toronto.
- RECRUITING
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer. The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy drug cisplatin or carboplatin, with a chemotherapy drug called paclitaxel. These are common chemotherapy drugs used in the treatment of women with cervical cancers.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- PROCEDURE Trachelectomy
Study Locations (4)
Ontario
- Sunnybrook Health Sciences Centre - Toronto
- Princess Margaret Cancer Centre - Toronto
Texas
- MD Anderson Cancer Centre - Houston
Quebec
- L'Hôtel-Dieu de Québec - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-02-11 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT04016389 shows while recruiting
NCT04016389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT04016389 reports a single indexed study location in Ontario, Texas, Quebec.
Frequently Asked Questions
What is clinical trial NCT04016389 about?
NCT04016389 is a clinical study titled "FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery". This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whet...
What is the current status of trial NCT04016389?
This trial is currently recruiting. It is a NA study. The enrollment target is 31 participants. The study started on 2020-02-11. Estimated completion is 2028-12.
What conditions does trial NCT04016389 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT04016389?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Trachelectomy (PROCEDURE).
Who is sponsoring clinical trial NCT04016389?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04016389 being conducted?
This trial has 4 study locations across Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04016389's enrollment target sits among peer trials
31 118th of 144 higher than 27 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
- NCT04561206 · 31 participants · Phase 2
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI